EUVIMEDEUVIMED entdecken
Crossref

Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression

Shuji Mikami iD, Ryuichi Mizuno, Nobuyuki Tanaka, Kyohei Hakozaki, Kimiharu Takamatsu, Mototsugu Oya

Pathology International · 2025-08 · 75 (8) · 403-413

DOI: 10.1111/pin.70030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology International, online erschienen am 02.06.2025. Verfasst von Shuji Mikami und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins c-met, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cabozantinib, a newly developed vascular endothelial growth factor receptor‐tyrosine kinase inhibitor (VEGFR‐TKI), is an effective treatment for advanced renal cell carcinoma (RCC). However, the molecular mechanisms responsible for the superior effectiveness of cabozantinib to other drugs remain unclear. Since cabozantinib inhibits AXL and c‐MET in addition to VEGFR, the expression of these molecules was immunohistologically examined in 110 cases of primary clear cell RCC (ccRCC) and eight of sunitinib (VEGFR‐TKI)‐treated primary ccRCC. AXL expression correlated with the primary tumor stage, while c‐MET expression correlated with distant metastasis, the histological grade, and overall survival. Furthermore, the number of programmed death‐ligand 1 (PD‐L1)‐positive tumor‐infiltrating immune cells was higher in ccRCC tissues with high c‐MET expression than in those with low c‐MET expression. The expression of AXL and c‐MET was higher in sunitinib‐treated ccRCC tissues than in untreated tissues. These results suggest that AXL and c‐MET play important roles in the progression of ccRCC and resistance to sunitinib. Furthermore, c‐MET may modify the immune microenvironment by inducing PD‐L1 expression in immune cells within RCC tissues. These molecular pathways may be related to responses to cabozantinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellReceptor Protein-Tyrosine KinasesProto-Oncogene Proteins c-metKidney NeoplasmsProto-Oncogene ProteinsB7-H1 AntigenHumansAxl Receptor Tyrosine KinaseMaleFemaleMiddle AgedAnilidesAgedSunitinibPyridinesProtein Kinase InhibitorsAdultAged, 80 and overBiomarkers, Tumor

Stichwörter der Autor:innen

AXLPD‐L1cabozantinibc‐METrenal cell carcinomatumor microenvironment

Substanzen

Receptor Protein-Tyrosine KinasesProto-Oncogene Proteins c-metProto-Oncogene ProteinsB7-H1 AntigenAxl Receptor Tyrosine KinasecabozantinibAnilidesCD274 protein, humanSunitinibAXL protein, human

Autor:innen und Institutionen

  • Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Diagnostic Pathology, National Hospital Organization Saitama Hospital, Saitama, Japan.
  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Shuji Mikami

Zitieren

APA

Mikami, S., Mizuno, R., Tanaka, N., Hakozaki, K., Takamatsu, K., & Oya, M. (2025). Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression. Pathology International, 75(8), 403-413. https://doi.org/10.1111/pin.70030

Vancouver

Mikami S, Mizuno R, Tanaka N, Hakozaki K, Takamatsu K, Oya M. Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression. Pathology International. 2025;75(8):403-413. doi:10.1111/pin.70030

BibTeX
@article{Mikami2025,
  author = {Mikami, Shuji and Mizuno, Ryuichi and Tanaka, Nobuyuki and Hakozaki, Kyohei and Takamatsu, Kimiharu and Oya, Mototsugu},
  title = {Increased Expression of AXL and c‐MET in High‐Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR‐TKI Treatment and PD‐L1 Expression},
  journal = {Pathology International},
  year = {2025},
  volume = {75},
  number = {8},
  pages = {403--413},
  doi = {10.1111/pin.70030}
}
Kostenlos starten →